An investigation on behalf of investors of electroCore, Inc. (NASDAQ: ECOR) shares over potential securities laws violations by electroCore, Inc. and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of electroCore, Inc. (NASDAQ: ECOR) concerning whether a series of statements by electroCore, Inc. (NASDAQ: ECOR regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Basking Ridge, NJ based electroCore, Inc., a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve (VNS) stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields.
In June 2018, electroCore completed its initial public offering (IPO) in which it sold 5.2 million shares of its common stock at $15.00 per share.

electroCore, Inc. reported that its annual Total Revenue rose from $0.811 million in 2017 to $0.992 million in 2018 and that its Net Loss increased from $35.79 million in 2017 to $55.82 million in 2018.

On May 14, 2019, electroCore, Inc. announced its financial results for first quarter 2019.

Shares of electroCore, Inc. (NASDAQ: ECOR) declined to as low as $2.82 per share on May 17, 2019.